Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Background: Financial toxicity (FT) is reported by up to 50% of cancer survivors and is associated with decline in HRQoL, delaying care and higher mortality. Early data in bladder cancer (BC) suggests the same. Existing data have largely focused on cohorts that have homogeneity in terms of race/ethnicity, insurance type and socioeconomic status. No thresholds for FT in BC have been defined. Hypothesis: Our central hypothesis is that FT is highly prevalent in BC and impacts HR-QoL and treatment decisions. Our secondary hypothesis is that sociodemographic factors will impact the extent and type of FT that is experienced. Methods/Approach: 140 patients with existing BC diagnosis who are receiving treatment at a large, public hospital (site 1) and a tertiary cancer center (site 2) will be recruited to complete validated instruments of (1) financial toxicity/distress, (2) general and disease specific QoL, items pertaining to coping strategies including non-adherence. Clinicopathologic data will be collected from the medical record. 20 patients in each arm who were screened as having FT will undergo semi-structured interviews and this will be synthesized with quantitative data. Concurrent validity between the 2 validated FT measures will be performed and used to generate thresholds of FT associated with risk of decline in HRQoL and non-adherence. A focus group of 8 urologic bladder cancer experts followed by an exploratory survey of 100 urologists, medical oncologists and radiation oncologists will be conducted to assess provider awareness and attitudes. Applicability: FT is a critical factor in these PSN questions and thus necessitates thorough investigation: 1.How does a patient with invasive BC choose between preserving and removing the bladder? 2. How do we improve patient education about expectations for recovery and treatment success after radical cystectomy? 3. How can caregivers of patients with metastatic BC reduce their burdens?
Similar projects All >
Sorted by: Start Date
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer


USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2020 - 2021



    1112 Oncology and Carcinogenesis

  • RCDC

    Mind and Body

  • RCDC

    Basic Behavioral and Social Science

  • RCDC

    Behavioral and Social Science

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Urologic Diseases




    7.1 Individual care needs

  • Health Research Areas

    Health services & systems